TC Biopharm Ltd. (TCB), of Glasgow, Scotland, disclosed a collaboration with Trinity College Dublin to accelerate in-house production of medicines based on donor cell banks for the treatment of solid tumors. TCB will manufacture GMP-compliant candidates that will be combined with its off-the-shelf tumor-targeted T-cell platform to generate candidates to treat a range of cancer types. Initial studies are planned for late 2019.